Evidence map›Paper›PMID 31548829›Full record

ArticleCurrent oncology (Toronto, Ont.)2019

Updates from the 2019 American Society of Clinical Oncology and European Hematology Association annual meetings: a Canadian perspective on high-risk cytogenetics in multiple myeloma.

R LeBlanc, K Song, D White, A Christofides, S Doucette

Open access · goldAbstract readConference Proceedings
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

R LeBlancUniversité de Montréal and Hôpital Maisonneuve-Rosemont, Montreal, QC.
K SongUniversity of British Columbia and Vancouver General Hospital, Vancouver, BC.
D WhiteDalhousie University and Queen Elizabeth iiHealth Sciences Centre, Halifax, NS.
A ChristofidesimpactMedicom Inc., Toronto, ON.
S DoucetteimpactMedicom Inc., Toronto, ON.
Fluidigm (Canada) · CAHôpital Maisonneuve-Rosemont · CAQueen Elizabeth II Health Sciences Centre · CAVancouver General Hospital · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The 2019 annual meetings of the American Society of Clinical Oncology and the European Hematology Association took place, respectively, in Chicago, Illinois, 31 May-4 June, and in Amsterdam, Netherlands, 13-16 June. At the meetings, results from key studies on the treatment of patients with relapsed or refractory multiple myeloma with high-risk cytogenetics were presented. Our meeting report describes those studies and includes interviews with investigators and commentaries by Canadian hematologists about the potential impact on Canadian practice.

Indexed as

Antineoplastic AgentsCanadaChromosome DeletionCytogenetic AnalysisHumansMultiple MyelomaNeoplasm Recurrence, LocalPrognosisTranslocation, GeneticTreatment OutcomeAntineoplastic Agentshigh-risk cytogeneticsmultiple myelomarefractory diseaseRelapsed disease

Identifiers

PMID31548829
PMCPMC6726268
OpenAlexW2970396729

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.